ライフサイエンスコーパス: blood glucose level

1 tures enabling potential seamless control of blood glucose level.

2 ny actions that can raise or reduce falls in blood glucose level.

3 ociation being altered depending on maternal blood glucose level.

4 islets play an essential role in regulating blood glucose level.

5 e overt graft loss observed via uncontrolled blood glucose level.

6 mproved glucose tolerance and down-regulated blood glucose level.

7 otein-coupled receptor (GPCR) that regulates blood glucose levels.

8 homeostasis of hepatic glycogen storage and blood glucose levels.

9 rect, simple and less invasive monitoring of blood glucose levels.

10 involves the release of hormones to restore blood glucose levels.

11 erated the liver injury and normalization of blood glucose levels.

12 lipotoxicity and is associated with improved blood glucose levels.

13 ocin [HFD/STZ]) to induce a mild increase in blood glucose levels.

14 action was observed without any reduction in blood glucose levels.

15 versed diastolic dysfunction, and normalized blood glucose levels.

16 GSK2141795 did not significantly influence blood glucose levels.

17 play important, opposing roles in regulating blood glucose levels.

18 corticoid receptor blockade lowered elevated blood glucose levels.

19 ic hypoglycemia and increased variability of blood glucose levels.

20 of the incretin peptide hormones regulating blood glucose levels.

21 x proteins, and albuminuria without changing blood glucose levels.

22 in levels in fasted mice, as well as fasting blood glucose levels.

23 significant dose-dependent reductions in fed blood glucose levels.

24 d tacrolimus/sirolimus also increased random blood glucose levels.

25 6 h but fell thereafter, concomitantly with blood glucose levels.

26 tract in the DIO model and increased fasting blood glucose levels.

27 g a sigmoidal kinetic response to increasing blood glucose levels.

28 to the mechanism by which RTEF-1 attenuates blood glucose levels.

29 ne of several peptide hormones that increase blood glucose levels.

30 ating insulin release and maintaining normal blood glucose levels.

31 parasympathetic cholinergic fibers increases blood glucose levels.

32 neogenesis, glucose intolerance, and fasting blood glucose levels.

33 increased adiposity and decreased control of blood glucose levels.

34 tional satisfaction are linked to changes in blood glucose levels.

35 with an irreversible and progressive drop of blood glucose levels.

36 ut did not counter leptin's ability to lower blood glucose levels.

37 duce sufficient insulin to properly regulate blood glucose levels.

38 ulin secretion and maintaining physiological blood glucose levels.

39 s which undergo exocytosis upon elevation of blood glucose levels.

40 Collectively, these changes can normalise blood glucose levels.

41 cial effects on food intake, body weight and blood glucose levels.

42 olecules in the liver and kidney to maintain blood glucose levels.

43 r example, blood permittivity depends on the blood glucose levels.

44 flozin, increase glucose excretion and lower blood glucose levels.

45 MN patches, leading to a gradual decrease in blood glucose levels.

46 Diabetic animals showed significantly higher blood glucose levels (10.8 +/- 0.7 vs. 8.4 +/- 0.5 mmol/

47 tolerance test in mice, fraction 16C reduced blood glucose level (181 +/- 10 mg/dL) in comparison to

48 dysfunction (E/E' 14 +/- 1), and normalized blood glucose levels (7.5 +/- 0.7 mmol/L).

49 nsive insulin therapy (IIT) targeting normal blood glucose levels (81-108 mg/dl) increases the incide

50 resulted in significantly increased fasting blood glucose levels, a blunted insulin response with de

51 red GcgR monoclonal antibody displayed lower blood glucose levels accompanied by elevated plasma ghre

52 HT decreased blood glucose levels, adipocyte size, and triglyceride a

53 mportantly, NT-ES-beta-cells maintain normal blood glucose levels after ablation of the mouse endogen

54 for dietary intake, body weight, and fasting blood glucose levels after islet transplantation.

55 ation with glucose dehydrogenase to regulate blood glucose level, alcohol dissolution into carboxylic

56 A lowered blood glucose level also was observed in overnight-faste

57 gliptin, an antidiabetic agent, which lowers blood glucose levels, also reduces postprandial lipid ex

58 tide that plays an important role regulating blood glucose levels, analogues of which are used for tr

59 fluid glucose level is representative of the blood glucose level and follows it without significant d

60 -)) display resistance to T1D as the rise in blood glucose level and islet inflammation were signific

61 s to assess the association between elevated blood glucose level and mortality in acute heart failure

62 that anti-CD44 antibody treatment decreases blood glucose levels and adipose tissue macrophage accum

63 ectly hyperactivate GK (GK activators) lower blood glucose levels and are being evaluated clinically

64 Offspring exhibited similar weight, blood glucose levels and baseline water and chow intake

65 type 2 diabetes drug, dapagliflozin, reduces blood glucose levels and body weight by inhibiting sodiu

66 he success of GLP-1-based agents in lowering blood glucose levels and BW, we hypothesized that an ind

67 in diagnosis of NDH and T2D, and changes in blood glucose levels and cardiovascular risk score betwe

68 ing increased body weight, visceral fat, and blood glucose levels and decreased leptin sensitivity.

69 s and benefits, the significance of abnormal blood glucose levels and diabetes as cardiovascular risk

70 Blood glucose levels and disease severities were analyze

71 Allograft survival was determined by fasting blood glucose levels and flow cytometric techniques were

72 of high PM2.5 exposure during pregnancy with blood glucose levels and GDM risk in Chinese women.

73 gh PM2.5 exposure during pregnancy increases blood glucose levels and GDM risk in Chinese women.

74 oral administration of ANC improved fasting blood glucose levels and glucose tolerance in hyperglyca

75 lockade in the NAc bidirectionally modulated blood glucose levels and glucose tolerance.

76 gs demonstrate good correlation of reference blood glucose levels and glucose values obtained with th

77 Insulin treatment reduced blood glucose levels and heart defects.

78 eatment with a carbohydrate-rich diet raised blood glucose levels and improved retinal function in Gc

79 KY sequence resulted in a reduction in basal blood glucose levels and increased circulating serum ins

80 nally, we show that 13d significantly lowers blood glucose levels and increases concomitant beta-cell

81 F-1(-/-) mice showed significantly increased blood glucose levels and insulin resistance, accompanied

82 Longitudinal changes in bodyweight, blood glucose levels and plasma insulin concentration we

83 n ventilation and CO2 sensitivity to restore blood glucose levels and prevent a fall in blood pH.

84 units exhibited significantly higher fasting blood glucose levels and produced more glucose than flox

85 1 and advanced type 2 diabetics to maintain blood glucose levels and prolong lives.

86 e that exogenous apoA-IV injection decreases blood glucose levels and stimulates a transient increase

87 he vasculature that affect the regulation of blood glucose levels and the development of atherosclero

88 ccordingly, the Rosa-Lkb1 mice had increased blood glucose levels and were intolerant to glucose chal

89 in the fruit fly brain that directly senses 'blood' glucose levels and reciprocally regulates the sec

90 proliferation, hepatic inflammation, fasting blood glucose level, and glucose intolerance, compared w

91 e demographic data, blood pressures, fasting blood glucose level, and lipid profile.

92 ed acoustic startle response, US expectancy, blood glucose levels, and arousal ratings.

93 UACR and 8-OHdG, low-density lipoprotein and blood glucose levels, and duration of diabetes in patien

94 Abnormal blood pressure, blood glucose levels, and fever in the setting of arteri

95 roved several metabolic parameters including blood glucose levels, and insulin and glucose tolerance.

96 Abnormalities of blood pressure, blood glucose levels, and temperature are prevalent in c

97 e best medical management of blood pressure, blood glucose levels, and temperature in pediatric patie

98 secreting alpha cells maintain physiological blood glucose levels, and their malfunction drives diabe

99 ogether hormonal control of blood volume and blood glucose levels, and thus adding to our understandi

100 The risk associated with an elevated blood glucose level appeared consistent across all subgr

101 mmencing insulin dosing when two consecutive blood glucose levels are > 180 mg/dL, targeting an upper

102 e indicates that pre-diagnostic diabetes and blood glucose levels are inversely related to glioma ris

103 slet activity persist, and relatively normal blood glucose levels are maintained.

104 l function; therefore, therapies that reduce blood glucose levels are of great interest in not only c

105 Blood glucose levels are tightly controlled by the coord

106 h of gray and white matter in children whose blood glucose levels are well within the current treatme

107 accurate, and non-invasive monitoring of the blood glucose level as an effective technique for diabet

108 echnology now allows real time monitoring of blood glucose levels as a time series, and thus the expl

109 both precise dosing in response to real-time blood glucose levels as well as a feasible and low-burde

110 y 98.3% degree of gelatinization and maximal blood glucose level at 30min).

111 ization ( approximately 53.8%) and a maximal blood glucose level at 60min (slower glycemic response)

112 The individual's blood glucose level at the time of obtaining saliva was

113 population with diabetes, the change in the blood glucose level at the time of scan across longitudi

114 Higher blood glucose levels at admission and during the first 3

115 effectively counterbalance a decline of the blood glucose level becomes even more pronounced in case

116 patients then underwent treatment to control blood glucose levels before end blood samples were taken

117 mns in the range of Glc-1 to Glc-20 and high blood glucose level being retained in greater quantity.

118 r rates of severe hypoglycemia, defined as a blood glucose level below 40 mg per deciliter (2.2 mmol

119 g insulin, glargine, resulted in fluctuating blood glucose levels between 91 and 443 mg/dL in type 1

120 Elevated blood glucose level (BGL) and NLR were strongly associat

121 Blood glucose level (BGL), National Institute of Health

122 n capability and a remarkable sensitivity of blood glucose levels (BGLs).

123 CREBH deficiency leads to reduced blood glucose levels but increases hepatic glycogen leve

124 urrent drugs for type 2 diabetes (T2D) lower blood glucose levels but they do not directly alleviate

125 of Cyp46a1(-/-) mice that had normal fasting blood glucose levels but up to a 1.8-fold increase in re

126 to participate significantly in maintaining blood glucose levels, but their contribution to endogeno

127 cted normal chow-fed mice showed upregulated blood glucose level by increasing gluconeogenesis, and u

128 GLP-1 is capable of regulating the blood glucose level by insulin secretion after administr

129 Pancreatic islets manage elevations in blood glucose level by secreting insulin into the bloods

130 ring trimester 1 increased 1-hour and 2-hour blood glucose levels by 1.40% (95% CI: 0.42, 2.37) and 1

131 pound 9m at 3, and 10 mpk po in feed lowered blood glucose levels by 89% and 94% at day 10, respectiv

132 Insulin regulates blood glucose levels by binding its receptor and stimula

133 2 (SGLT2) inhibitors were developed to lower blood glucose levels by inhibiting glucose reabsorption

134 Metformin lowers blood glucose levels by inhibiting hepatic glucose produ

135 ng a basal clamp, we found that BDNF lowered blood glucose levels by potently suppressing HGP, withou

136 glucose homeostasis in vivo Nrf2 suppresses blood glucose levels by protecting pancreatic beta cells

137 Modulation of blood glucose levels by suppressing insulin release was

138 Proper control of the blood glucose level can delay, and to a greater extent,

139 hat for a person with type II diabetes, both blood glucose levels can be controlled and healthy oscil

140 an impact of a given meal on an individual's blood glucose levels can serve as the engine for a new g

141 refore, to stably and accurately control the blood glucose level, CGM should be stable and accurate f

142 report, we make the unexpected finding that blood glucose levels change significantly during the cou

143 Blood glucose levels changed in accordance with how much

144 slet-seeded biomaterial coupled with reduced blood glucose levels, collectively resulting in increase

145 Only 8% monitored their blood glucose levels daily, 15% monitored weekly, and 10

146 ot fibroblast cells significantly controlled blood glucose levels, delayed diabetes onset, ameliorate

147 on to diabetes in patients who have abnormal blood glucose levels detected by screening.

148 Of note, non-obese diabetic mice with high blood glucose levels displayed a healthy colonic mucus b

149 Sulphonylurea therapy rapidly normalizes blood glucose levels, dissipates glycogen stores, increa

150 Interestingly, blood-glucose-levels drop severely in treated animals, p

151 Hepatic glucose production (HGP) maintains blood glucose levels during fasting but can also exacerb

152 odulate insulin secretion to better regulate blood glucose levels during periods of changing metaboli

153 ogenesis is important for maintaining steady blood glucose levels during starvation and through light

154 or null mice and also helps maintain fasting blood glucose levels, ensuring an adequate supply of nut

155 e hyperglycemia was defined as 2 consecutive blood glucose levels exceeding 216 mg/dL at least 3 hour

156 Hemoglobin A1c (HbA1c) and fasting blood glucose levels (FBGLs) were recorded.

157 [PD], marginal bone loss [MBL]) and fasting blood glucose levels (FBGLs) were recorded.

158 as it gives the stable and reliable value of blood glucose levels for a period of 90-120 days.

159 In addition, fasting blood glucose levels for DKO mice were significantly low

160 oximately four days and sustained control of blood glucose levels for more than a week in mice.

161 icant correlation was found between tear and blood glucose levels for multiple rabbits, suggesting th

162 successfully normalized and maintained host blood glucose levels for over 370 days in the absence of

163 failure, muscle weakness, and hyperglycemia (blood glucose level >150 mg/dL [to convert to millimoles

164 s, tight glycemic control targeting a normal blood glucose level has not been shown to improve outcom

165 c blood glucose sensors at lower than normal blood glucose levels has blocked their practical applica

166 radation of the incretins and the control of blood glucose levels have been demonstrated in biologica

167 tes duration, being under insulin treatment, blood glucose level, having non-communicable diseases we

168 s with type 2 diabetes and poorly controlled blood glucose levels (hemoglobin A1c (HbA1c) levels of >

169 Lower fasting blood glucose levels, higher insulin, and lower islet am

170 bumin excretion, glomerular hyperfiltration, blood glucose levels, histological deterioration and sys

171 erval (CI): 1.06, 1.52), an elevated fasting blood glucose level (HR = 1.20, 95% CI: 1.03, 1.39), and

172 zed formulation effectively lowered the high blood glucose level in a T2D db/db mice model to the nor

173 2) has emerged as a promising way to control blood glucose level in diabetes patients.

174 ates whether perceived time has an effect on blood glucose level in people with type 2 diabetes.

175 sample also showed significant drops of the blood glucose level in rats derived from hypoglycemic ac

176 d hemoglobin (HbA1c), reflecting the average blood glucose level in the proceeding 2-3 months, is rec

177 aced in the rat buccal pouch in vivo lowered blood glucose levels in a dose-dependent manner (up to 5

178 ialysis - as a means to dynamically modulate blood glucose levels in awake, freely moving mice while

179 Leptin treatment normalized blood glucose levels in both groups.

180 A rapid decrease occurred in blood glucose levels in both models, and all animals rea

181 tively enhanced GK translocation and reduced blood glucose levels in diabetic animals.

182 lly actuated to deliver Metformin and reduce blood glucose levels in diabetic mice.

183 after short-term transplantation, and reduce blood glucose levels in diabetic mice.

184 e appeared as viable therapeutics to control blood glucose levels in diabetic patents.

185 active form with corresponding reduction in blood glucose levels in diabetic rats.

186 ) were effective in acutely lowering fasting blood glucose levels in diet induced obese hyperglycemic

187 t sufficient over the short term to maintain blood glucose levels in fasted, fat-depleted mice.

188 cant amounts of glucose in order to maintain blood glucose levels in healthy subjects.

189 Statin therapy is known to increase blood glucose levels in humans.

190 cagon-like peptide-1 PODs was able to reduce blood glucose levels in mice for up to 5 d, 120 times lo

191 n of depot forming GLP-1-ELP fusions reduced blood glucose levels in mice for up to 5 days, 120 times

192 iac malformations, we observed that maternal blood glucose levels in models including insulin were st

193 sEPD of insulin was found to maintain blood glucose levels in normal range for at least 6h in

194 le subcutaneous injection failed to maintain blood glucose levels in normal range.

195 es require daily insulin therapy to maintain blood glucose levels in normoglycemic ranges to prevent

196 ure D3S5G dose-dependently decreased fasting blood glucose levels in obese C57BL/6J mice, and decreas

197 lights the importance of close monitoring of blood glucose levels in patients taking rapamycin as an

198 tors (AMG-1694 and AMG-3969) that normalized blood glucose levels in several rodent models of diabete

199 nd on transplantation were able to normalize blood glucose levels in streptozotocin diabetic NOD/SCID

200 Blood glucose levels in the glucagon-like peptide-1 grou

201 ion of exogenous insulin aimed at regulating blood glucose levels in the normoglycemic range.

202 The liver responds to an increase in blood glucose levels in the postprandial state by uptake

203 n directly into the VMN also lowered fasting blood glucose levels in uncontrolled insulin-deficient d

204 ore and after beverage consumption show that blood glucose levels increase when participants believe

205 N subsets appear to be capable of regulating blood glucose levels independently from the central nerv

206 Outside of its effects on blood glucose levels, insulin resistance is also associa

207 ghrelin receptor antagonist further reduced blood glucose levels into the markedly hypoglycemic rang

208 however, unsettled as to whether an elevated blood glucose level is the cause or consequence of incre

209 Tracking the fluctuations in blood glucose levels is important for healthy subjects a

210 es of hypoglycemia with severity of level 2 (blood glucose level, <54 mg per deciliter) or level 3 (s

211 Blood glucose levels measured four times before and afte

212 or the development of biosensing systems for blood glucose level monitoring will be discussed, in vie

213 al lipidome between participants with normal blood glucose levels (n = 26) and those with type 2 diab

214 aumatic brain injury (TBI), although optimal blood glucose levels needed to maximize outcomes for the

215 I, -2.9% to -1.4%]) (24 studies) and fasting blood glucose level (net change, -0.12 mmol/L [-2.2 mg/d

216 t Fxyd2(-/-) mice showed significantly lower blood glucose levels, no signs of peripheral insulin res

217 cardiovascular risk factors such as abnormal blood glucose levels, obesity, and smoking are not inclu

218 ed countries, including lower risk of raised blood glucose levels, obesity, tobacco, and aging, where

219 in to mimic the changes in serum insulin and blood glucose levels observed after intranasal insulin.

220 In contrast, the lowered fasting blood glucose levels observed in ghrelin receptor-defici

221 eive insulin glargine (with a target fasting blood glucose level of </=95 mg per deciliter [5.3 mmol

222 Hyperglycemia was defined as a blood glucose level of 200 mg/dL or greater.

223 controlled diabetes mellitus, with a fasting blood glucose level of 410 mg/dL (22.8 mmol/L) and a hem

224 The rate of documented hypoglycemia with a blood glucose level of 55 mg per deciliter (3.1 mmol per

225 e of an insulin-dosing algorithm targeting a blood glucose level of 80 to 110 mg per deciliter [4.4 t

226 it from tight glycemic control targeted to a blood glucose level of 80 to 110 mg per deciliter, as co

227 8) We suggest that clinicians target a blood glucose level of less than 180 mg/dL in patients r

228 ibed on page 3115, effectively regulates the blood glucose level of type-1 diabetic mice, achieving a

229 stant nutrition and controlled exercise, the blood glucose levels of a person with type I diabetes ca

230 Relative to maternal blood glucose levels of infants without cardiac malforma

231 The NF-kappaB inhibition did not affect blood glucose level or body weight.

232 rategies vary significantly, irrespective of blood glucose level or diabetic status.

233 criteria are present - 'D', either elevated blood glucose levels or a family history of diabetes mel

234 ot have hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes to behavioral counseli

235 actors (hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes).

236 The level of HbA1c reflects the mean blood glucose level over the prior 2-3 months and it is

237 onitored daily food intake, body weight, and blood glucose levels over a 3-week period.

238 MG were significantly associated with higher blood glucose levels (P = 3.9E(-4)).

239 It is known that even normal blood glucose levels physiologically inhibit glycogen ph

240 own that resveratrol supplementation reduces blood glucose levels, preserves beta-cells in islets of

241 , studies seldom focus precisely on maternal blood glucose level prior to pregnancy.

242 expression of ATP-insensitive KATP channels, blood glucose levels rapidly rose to >500 mg/dL.

243 ults suggest a mechanism whereby oscillatory blood glucose levels recruit non-oscillating islets to e

244 d release of exendin-4, prolonged control of blood glucose level, reduced dosing frequency, and impro

245 as evident in diabetes patients with similar blood glucose levels regardless of which glycated hemogl

246 nt reactive oxygen species production, while blood glucose levels remained unchanged.

247 ediated by systolic blood pressure (SBP) and blood glucose levels, respectively.

248 when glucose uptake is compromised, raising blood glucose levels restores collagen synthesis in Runx

249 When blood glucose levels return to normoglycemia beta-cell m

250 re and promoted weight gain without altering blood glucose levels, silencing VMNCCKBR neurons decreas

251 rs, obtaining a close correlation with their blood glucose levels, simplifying and reducing the costs

252 tudies to determine whether tear glucose and blood glucose levels sufficiently correlate for applicat

253 ly, we found that brain endozepines modulate blood glucose levels, suggesting their involvement in a

254 and health state of the animals with normal blood glucose levels (Table 1).

255 ived time will have a greater influence over blood glucose level than actual time.

256 with Glu-OC experienced significantly lower blood glucose levels than Glu-OCN-treated wild-type mice

257 /-):Ins2(+/Akita) mice showed a reduction in blood glucose levels that correlated with the ameliorati

258 rojecting melanocortinergic pathway elevates blood glucose levels that is associated with increased e

259 he lumen of rat jejunum caused a decrease in blood glucose levels that was PIP peptide and insulin do

260 , consisting of duration of obesity, fasting blood glucose levels, the presence of high blood pressur

261 c potency in the suppression of postprandial blood glucose levels thereby possibly preventing diabete

262 of Langerhans are the regulators of in vivo blood glucose levels through the secretion of endocrine

263 ormulation achieved a rapid reduction of the blood glucose level to the normal range within <12 h and

264 Moreover, GLP1(HepoK) decreased blood glucose level to the same level as GLP1(WT) in mic

265 Blood glucose level, total leukocyte count, neutrophil c

266 ed mice exhibited reductions in body weight, blood glucose levels, total cholesterol (TC), leptin, to

267 the Ay-yellow obese gene (KKAy) mice lowered blood glucose levels toward the normoglycemic range.

268 The authors demonstrate that high blood glucose levels trigger neutrophil release of S100

269 macodynamic effect and significantly reduced blood glucose levels up to 6 h postdose.

270 ce, both compounds significantly lowered fed blood glucose levels (up to 58%).

271 glucoregulatory system (BCGS) that can lower blood glucose levels via both insulin-dependent and -ind

272 Empagliflozin reduces blood glucose levels via inhibition of the sodium glucos

273 During treatment, the mean blood glucose level was 118 mg/dL (6.6 mmol/L) in the in

274 The target blood glucose level was 90-120 mg/dL for patients admitt

275 In the fully adjusted model, an elevated blood glucose level was an independent predictor of 30-d

276 control) in the percentage of time that the blood glucose level was lower than 70 mg per deciliter w

277 The blood glucose level was maintained to below the therapeu

278 outcome was the percentage of time that the blood glucose level was within the target range of 70 to

279 patient with normal fasting ( = pre-feeding) blood glucose levels was matched in terms of gestational

280 As expected, pre-diagnostic blood glucose levels were inversely related to glioma ri

281 Blood glucose levels were measured before and after the

282 Changes in blood glucose levels were measured in 46 participants wi

283 Fasting blood glucose levels were measured using a glucometer.

284 dical database, nutritional information, and blood glucose levels were merged for analysis.

285 Body weights, blood glucose levels were monitored throughout the study

286 blood vessel ablation, basal and stimulated blood glucose levels were only slightly increased, while

287 which plasma insulin levels were identical, blood glucose levels were reduced in G6pc2 KO mice, agai

288 In Keap1MuKO mice, blood glucose levels were significantly downregulated an

289 Mean fasting blood glucose levels were significantly higher in dogs w

290 Under HFD conditions, blood glucose levels were significantly lower (by >30%)

291 After cessation of sub-acute dosing, fasting blood glucose levels were significantly lower in ZDF rat

292 Within 17 weeks blood glucose levels were stabilized in animals injected

293 ARA 290 treatment significantly improved the blood glucose levels when compared to those of control a

294 lone elicited a rapid decline in circulating blood glucose levels, which appeared to induce endogenou

295 in therapy was designed to rapidly normalize blood glucose levels with bolus doses of insulin and rap

296 Normalization of blood glucose levels with GCGR-blocking antibody unexpec

297 xploit a new cellular mechanism for lowering blood glucose levels with reduced potential for hypoglyc

298 r disease was associated with improvement in blood glucose levels, with evidence of altered expressio

299 bility of this insulin conjugate to regulate blood glucose levels within a normal range while mitigat

300 l insulin, causing a significant decrease in blood glucose levels within one hour.